Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.00M$17.00Mderived+46.3% vs Q4 2022 Net Income-$12.89M-$12.89MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$11,624,000+42.2% Operating Incomederived-$12,278,000N/M Operating Cash Flowderived-$11,051,000N/M Free Cash Flowderived-$11,256,000N/M Margins · derivedGross margin68.4%−2.0 pt vs Q4 2022
Operating margin-72.2%+9.0 pt vs Q4 2022
Net margin-75.8%+10.0 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 22, 2024 · 82 d after period end